Wu Z et al., 2013: Human liver microsome and recombinant P450 study identifying the enzymes that hydroxylate fenbendazole. Fenbendazole hydroxylation was preferentially catalysed by CYP2C19 and CYP2J2, not by CYP3A4.
In conclusion, our data for the first time suggest that albendazole hydroxylation is primarily catalyzed by CYP2J2, whereas fenbendazole hydroxylation is preferentially catalyzed by CYP2C19 and CYP2J2.
Wu Z et al., 2013: Human liver microsome and recombinant P450 study identifying the enzymes that hydroxylate fenbendazole. Fenbendazole hydroxylation was preferentially catalysed by CYP2C19 and CYP2J2, not by CYP3A4. In vitro study type: human liver microsomes from 14 donors plus 10 recombinant P450 isoforms; no patients, no dose, no route. Country: South Korea (Kyungpook National University, Daegu). Funder: not stated in the PubMed record; no grant list. Declared conflicts: none recorded in the PubMed XML. Maker of drug tested: fenbendazole and albendazole standards, supplier not stated. Comparator: isoform-selective inhibitors and correlation with marker activities. Excerpt is the abstract's conclusion sentence. Also filed as FBE-42 (claims C1, C5). Study type: lab.
